Carmen Bozic Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 4 months ago
Carmen Bozic has an estimated net worth of at least $32.4 million*, as of Oct. 29, 2025. They own 40,063 shares of VRTX stock. They have sold 49,914 shares of VRTX stock since 2021, for an estimated $18.7 million.
Carmen Bozic $VRTX SEC Form 4 Insider Trading
Carmen Bozic has filed a total of 13 insider trades in $VRTX since 2021. Their most recent trade was a sale of 2,329 shares, made on Feb 27, 2026. Their largest trade was a sale of 5,651 shares, made on Oct 31, 2023. We estimate that they now own 40,063 shares of $VRTX, worth an estimated $13.7 million.
Insider Trading at $VRTX
There have been a total of 559 insider trades reported at $VRTX since 2021, with 40,000 shares purchased and 1.1 million shares sold. The most active insider traders in $VRTX stock have been David Altshuler, Ourania Tatsis, and Bastiano Sanna. The most recent trade was a sale of 2,329 shares reported by Carmen Bozic (EVP and CMO), made on Feb 27, 2026.
History of Insider Stock Trades by Carmen Bozic
| Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
|---|---|---|---|---|
VRTX
|
Sale | 2,329 | Feb 27, 2026 | March 3, 2026, 5:25 p.m. |
|
VRTX
|
Sale | 2,280 | Aug 07, 2024 | Aug. 8, 2024, 4:06 p.m. |
|
VRTX
|
Sale | 2,280 | Jul 24, 2024 | July 25, 2024, 4:06 p.m. |
|
VRTX
|
Sale | 2,280 | Jul 10, 2024 | July 12, 2024, 4:07 p.m. |
|
VRTX
|
Sale | 2,280 | Jun 26, 2024 | June 28, 2024, 4:04 p.m. |
|
VRTX
|
Sale | 2,280 | Jun 12, 2024 | June 13, 2024, 4:11 p.m. |
|
VRTX
|
Sale | 2,280 | May 29, 2024 | May 31, 2024, 4:19 p.m. |
|
VRTX
|
Sale | 5,650 | Nov 14, 2023 | Nov. 16, 2023, 5:15 p.m. |
|
VRTX
|
Sale | 5,651 | Oct 31, 2023 | Nov. 2, 2023, 4:07 p.m. |
|
VRTX
|
Sale | 5,651 | Oct 17, 2023 | Oct. 19, 2023, 4:18 p.m. |
|
VRTX
|
Sale | 5,651 | Oct 03, 2023 | Oct. 5, 2023, 4:30 p.m. |
|
VRTX
|
Sale | 5,651 | Sep 19, 2023 | Sept. 21, 2023, 4:15 p.m. |
|
VRTX
|
Sale | 5,651 | Sep 05, 2023 | Sept. 7, 2023, 4:29 p.m. |
$VRTX Executives and Stock Owners with Insider Trades
-
David Altshuler, EVP, Global Research and CSO
-
Ourania Tatsis, EVP, Chief Reg. & Quality Off.
-
Bastiano Sanna, EVP, Cell & Genetic Therapies
-
Stuart A Arbuckle, EVP, COO
-
Jeffrey M Leiden, Executive Chairman
-
Charles F Jr Wagner, EVP & Chief Financial Officer
-
Reshma Kewalramani, CEO & President
-
Joy Liu, SVP, General Counsel
-
Kristen Ambrose, SVP & Chief Accounting Officer
-
Amit Sachdev, EVP Chief Patient & Ext Af Off
-
Carmen Bozic, EVP and CMO
-
Edward Morrow Iii Atkinson, EVP, Chief Technical Ops. Off.
-
Jonathan Biller, EVP and Chief Legal Officer
-
David Altshuler, EVP, Chief Scientific Officer
-
Mark E. Bunnage, EVP, Chief Scientific Officer
-
Amit Sachdev, EVP, Chief Patient Officer
-
Charles F Jr Wagner, EVP, CO & FO
-
Duncan Mckechnie, EVP, Chief Commercial Officer
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.